The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men

被引:23
作者
Matsuo, Tomohiro [1 ]
Miyata, Yasuyoshi [1 ]
Kakoki, Katsura [1 ]
Yuzuriha, Miki [1 ]
Asai, Akihiro [1 ]
Ohba, Kojiro [1 ]
Sakai, Hideki [1 ]
机构
[1] Nagasaki Univ, Grad Sch Biochem Sci, Dept Urol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
来源
BMC UROLOGY | 2016年 / 16卷
关键词
Mirabegron; Elderly male; Overactive bladder; alpha 1-adrenergic blockers; OVERACTIVE BLADDER SYMPTOMS; BETA(3)-ADRENOCEPTOR AGONIST; EXTENDED-RELEASE; DOUBLE-BLIND; TOLERABILITY; SAFETY; PHASE-3;
D O I
10.1186/s12894-016-0165-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Mirabegron is a beta 3-adrenoreceptor agonist developed for treatment of overactive bladder (OAB). alpha 1-Adrenergic receptor blockers are effective for lower urinary tract symptoms (LUTS) in male patients. However, the efficacy of mirabegron additional treatment in elderly male patients with persistent male LUTS, especially in OAB after monotherapy with alpha 1-adrenergic blockers, is not fully understood. Methods: This study was conducted in male LUTS patients who were >= 65 years of age and had persistent OAB symptoms, regardless of whether they took an alpha 1-adrenergic receptor blocker orally. Before and 12 weeks after mirabegron additional therapy (50 mg once daily), we evaluated the efficacy of this treatment using the Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS), and changes in the maximum flow rate (Qmax) and post-void residual urine volume (PVR). We evaluated patients overall and divided into two groups by age: young-old (from 65 to 74 years old) and old-old (from 75 to 84 years old). Results: Fifty men were enrolled in this study. Mirabegron additional therapy improved the total OABSS, total IPSS, and IPSS-quality of life (QOL) score. The voided volume (VV) and Qmax improved after treatment in patients overall. However, there was no significant change in PVR. The total OABSS, total IPSS, and IPSS-QOL score significantly improved in both of the young-old and old-old groups. However, a significant increasing of VV was detected in the young-old group. There were no significant differences in the Qmax or PVR in either group. Conclusions: Mirabegron additional therapy was effective for male patients whose persistent LUTS and particularly OAB was not controlled with alpha 1-adrenergic receptor blocker monotherapy, and mirabegron did not have negative effects on voiding function. Additionally, mirabegron additional therapy was considered effective regardless of patient age.
引用
收藏
页数:8
相关论文
共 30 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]  
[Anonymous], DRUG SAF UPD MIR BET
[3]   Patient-reported reasons for discontinuing overactive bladder medication [J].
Benner, Joshua S. ;
Nichol, Michael B. ;
Rovner, Eric S. ;
Jumadilova, Zhanna ;
Alvir, Jose ;
Hussein, Mohamed ;
Fanning, Kristina ;
Trocio, Jeffrey N. ;
Brubaker, Linda .
BJU INTERNATIONAL, 2010, 105 (09) :1276-1282
[4]   Chronic Constipation in the Elderly [J].
Bouras, Ernest P. ;
Tangalos, Eric G. .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2009, 38 (03) :463-+
[5]  
Brown JS, 2000, AM J MANAG CARE, V6, pS574
[6]   Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses [J].
Buser, Nora ;
Ivic, Sandra ;
Kessler, Thomas M. ;
Kessels, Alfons G. H. ;
Bachmann, Lucas M. .
EUROPEAN UROLOGY, 2012, 62 (06) :1040-1060
[7]   Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With α-Blockers [J].
Chapple, Christopher ;
Herschorn, Sender ;
Abrams, Paul ;
Sun, Franklin ;
Brodsky, Marina ;
Guan, Zhonghong .
EUROPEAN UROLOGY, 2009, 56 (03) :534-541
[8]   The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis [J].
Chapple, Christopher R. ;
Khullar, Vik ;
Gabriel, Zahava ;
Muston, Dominic ;
Bitoun, Caty Ebel ;
Weinstein, David .
EUROPEAN UROLOGY, 2008, 54 (03) :543-562
[9]   Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year [J].
Chapple, Christopher R. ;
Kaplan, Steven A. ;
Mitcheson, David ;
Blauwet, Mary Beth ;
Huang, Moses ;
Siddiqui, Emad ;
Khullar, Vik .
INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (10) :960-967
[10]   Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder [J].
Chapple, Christopher R. ;
Kaplan, Steven A. ;
Mitcheson, David ;
Klecka, Jiri ;
Cummings, Jana ;
Drogendijk, Ted ;
Dorrepaal, Caroline ;
Martin, Nancy .
EUROPEAN UROLOGY, 2013, 63 (02) :296-305